Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of BI 1839100 in healthy Japanese men
jRCT2071230027Phase 1Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial comparing BI 1839100 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
BI 1839100
Beyond the preview
Go deeper on jRCT2071230027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230027.